After assisting BioTrack Capital in completing its fundraising for RMB Fund Phase I, JunHe recently acted again as the legal advisor to the company and provided legal services for its fundraising for RMB Fund Phase II. This phase raised RMB 3 billion and achieved over 70% reinvestment from existing investors, including several market-based mother funds, well-known insurance institutions, government-guided funds, listed companies and industrial investors.
Founded in 2017, BioTrack Capital is a professional investment institution focusing on investing in and incubating outstanding healthcare startups in the Chinese market. To date, BioTrack Capital has invested in a number of high quality companies and has built a strong portfolio of investments through its extensive presence in the healthcare sector. Many of the companies in BioTrack's portfolio have grown to become industry leaders, such as Abogen, Hinova, Obio, Huihe Medical, Jingfeng Technology, Calibra, MediTrust Health, NewMed, Xihua Scientific, Asieris and Innovex.
As the legal advisor of BioTrack Capital, JunHe participated in the preparation, establishment and fundraising of this phase, including assisting in designing the fund structure, drafting a full set of legal documents for the fundraising, assisting in negotiations with the various investors, conducting investor suitability verification and assisting in the fund closing. The project team utilised their vast experience in the formation of funds to provide professional and rigorous legal services to BioTrack Capital, including the provision of comprehensive advice during the drafting, negotiation and revision of the relevant legal documents, which was highly recognized by BioTrack Capital.
The lead partners of this project were WANG, Yi and CHEN, Yan.